Sign inJoin waitlistJoin the waitlist

Steven Treon

Director, Bing Center for Waldenström's Macroglobulinemia · Mass General Brigham

Credentials: · · ·

History

Bing Center for Waldenström's Macroglobulinemia · Mass General Brigham
Present

Hematology and Medical Oncology
Massachusetts General Hospital
1996–1999
Internal Medicine
Boston University Medical Center
1993–1996
Boston University
Boston University School of Medicine
1989–1993

Research

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood · 2022 · 1,363 citations
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
New England Journal of Medicine · 2012 · First of 19 authors · Corresponding · 994 citations
Ibrutinib in previously treated Waldenström's macroglobulinemia
New England Journal of Medicine · 2015 · First of 27 authors · 796 citations

Jorge Castillo
160 papers
Ken Anderson
109 papers
Andrew Branagan
59 papers
Irene Ghobrial
53 papers · 12 as a fellow
Shayna Sarosiek
49 papers
Nikhil Munshi
40 papers
MM
Manit Munshi
31 papers
NR
Noopur Raje
29 papers · 17 as a resident
CF
Catherine Flynn
26 papers
Paul Richardson
26 papers
JM
Jeffrey Matous
23 papers
Lia Palomba
22 papers

Grants

SPORE in Multiple Myeloma
National Cancer Institute · P50
Project lead · $2.1M · Dana-Farber Cancer Inst
2003–2025
Novel Serotherapy Strategies--Plasma Cell Malignancies
National Cancer Institute · K23
Contact PI · $633.6K · Dana-Farber Cancer Inst
2000–2005

Clinical trials

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
Principal investigator · Withdrawn · Phase 1
Dana-Farber Cancer Institute
2020
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Principal investigator · Terminated · Phase 1
Dana-Farber Cancer Institute
2017–2022
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2016–2022
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2012–2018